Auxesis Pharma is a Swedish pharmaceutical company developing innovative medicines for local skin pain and irritation in both humans and animals.
Our pharmaceutical development in Sweden is built on proprietary patents, long-term scientific research and a clear vision: to improve the quality of life for people living with skin-related conditions.
Auxesis Pharma is a Swedish pharmaceutical company with patented technology and a growing product portfolio.
We lead innovation in blocking local skin pain and irritation, as well as promoting healing and shortening recovery time following aesthetic treatments.
Built on scientific research and patented technology, we develop products that rapidly relieve and eliminate skin pain in simple, practical formats for consumers and healthcare professionals.
Parent company and central securities register company that holds the rights to the Group’s patents in selected medical research areas. The focus is to develop innovative medicines for localized pain and irritation in the skin — for both humans and animals.
Subsidiary founded in 2024. The company is responsible for prototype manufacturing and will hold a license to produce and market our medical products in the Nordic region, as well as manage licenses for the rest of the world. A dedicated factory will be established in the future to ensure quality, traceability, and efficient deliveries.
www.auxesismedtech.comSubsidiary focused on the animal care market, primarily dogs and livestock. Here we develop topical solutions for skin pain and irritation in animals, with the aim of reducing suffering and the need for systemic medications.
Behind Auxesis is a multidisciplinary team with experience in pharmaceutical development, research, entrepreneurship, and industry.
Together, we drive Auxesis from scientific discovery to market-ready products, with science, quality, and patient benefit at the core.
Chairman & Founder
Roar Adelsten is the founder of Auxesis Pharma Holding AB, Auxesis MedTech AB and Auxesis Animal Care AB.
He has nearly 30 years of experience in the pharmaceutical industry as CEO, Field Manager and Medical Consultant, including at Pfizer AS in Norway, and has worked in Sweden, Norway and the United States with reconstructive orthopedic surgery, orthopedics, surgical instruments, and joint and bone arthroplasty.
B.Sc. Medical Sciences, Toxicologist, IHM
Peter Åberg is CEO, business advisor, and a member of the ASA.P® drug development team.
He has more than 20 years of leadership and organizational development experience within medtech, pharmaceuticals, and manufacturing, serving in executive positions including CEO and Sustainability Director.
Peter holds a Bachelor's degree in Medical Sciences with specialization in Toxicology, is a UN representative, and works with international sustainability standards in leadership, environmental management, and business development.
Board Member & Business Development, Cosmeceuticals
Anna Tenstam has more than 35 years of international leadership experience across the pharmaceutical, diagnostics, medical technology, and medical aesthetics industries. She has held senior executive positions, including CEO and Chair, in international companies and has been involved in numerous mergers and acquisitions, successful exits, and IPOs.
Anna has extensive international board experience and is also actively engaged in several professional networks and organizations as a business developer and investor.
Head of Brand & Product Strategy
Helena Adelsten is responsible for the development of Auxesis' brands and product platforms. She works with strategy, concept development, product identity, design, and digital communication.
She has been a driving force behind the development of Cutivelle™ and Lenvée™, leading the work from concept and brand strategy to digital presence, marketing materials, and commercial positioning. With an academic background in IT and Economics, she combines technology, design, and business development to support the company's innovation.
Chief Financial Officer (CFO)
Chairman & Founder
Roar Adelsten is the founder of Auxesis Pharma Holding AB, Auxesis MedTech AB and Auxesis Animal Care AB.
He has nearly 30 years of experience in the pharmaceutical industry as CEO, Field Manager and Medical Consultant, including at Pfizer AS in Norway, and has worked in Sweden, Norway and the United States with reconstructive orthopedic surgery, orthopedics, surgical instruments, and joint and bone arthroplasty.
B.Sc. Medical Sciences, Toxicologist, IHM Business School
Peter Åberg is CEO, business advisor, and a member of the ASA.P® drug development team.
He has more than 20 years of leadership and organizational development experience within medtech, pharmaceuticals, and manufacturing, serving in executive positions including CEO and Sustainability Director.
Peter holds a Bachelor's degree in Medical Sciences with specialization in Toxicology, is a UN representative, and works with international sustainability standards in leadership, environmental management, and business development.
Board Member & Business Development, Cosmeceuticals
Anna Tenstam has more than 35 years of international leadership experience across the pharmaceutical, diagnostics, medical technology, and medical aesthetics industries. She has held senior executive positions, including CEO and Chair, in international companies and has been involved in numerous mergers and acquisitions, successful exits, and IPOs.
Anna has extensive international board experience and is also actively engaged in several professional networks and organizations as a business developer and investor.
Board Member
Lars-Olof Peterson is an experienced business advisor with expertise in executive management, corporate strategy, and business development. He has held several senior executive positions, including CEO roles within the medical technology industry, and has served as a board member of Swedish Medtech.
He has also worked extensively with standardization and regulatory matters within the medtech sector through assignments for ISO and SIS.
Lars-Olof is currently CEO of VD-stödet i Sverige AB.
Intellectual Property, Commercial Law & Dispute Resolution
Peter Hedberg specializes in intellectual property, commercial law agreements, and dispute resolution. He is an expert in intellectual property law, marketing law, and commercial law with extensive experience in strategic legal advisory services.
Peter has worked with IP strategies, infringement proceedings, and commercial matters for both Swedish and international companies and is a highly regarded advisor in complex business transactions.
Medical Advisor and Product Developer at Auxesis Pharma AB
Professor and physician with extensive experience and internationally recognized expertise in topical medicine, intensive care, and burn care.
Former Head of the Burn Center and Chief of Staff at the Department of Anesthesiology and Intensive Care, Linköping University Hospital (1999–2004).
President of the European Burns Association (EBA) (2007–2009).
Director of Research and Development for the Swedish Intensive Care Registry (2009–2013).
Vice President of Linköping University (2015–2018).
President of the International Society for Burn Injuries (ISBI).
Former member of the American Burn Association Burn Center Verification Committee.
Supervisor of more than 40 PhD students and principal investigator in more than 300 clinical trials, from Phase I to Phase IV.
Author and co-author of more than 350 peer-reviewed scientific publications, as well as several book chapters and textbooks.
MD, Specialist in Dermatology and Medical Advisor at Auxesis Pharma AB
Licensed physician and specialist in dermatology, serving as Medical Advisor to Auxesis Pharma.
Began her career in dermatology at the Department of Dermatology at Lausanne University Hospital, Switzerland.
Became a board-certified specialist in dermatology at Karolinska University Hospital, Solna, in 2009.
Completed additional specialist training at the Department of Reconstructive Plastic Surgery at Karolinska University Hospital.
Also completed advanced training in dermatologic surgery at the University of La Jolla, San Diego, USA.
M.Sc. Pharm., PhD
RegSmart Life Science
Agneta Larhed has served as Regulatory Advisor to Auxesis since August 2024, focusing on pharmaceutical quality and regulatory requirements for clinical development.
Her work includes quality requirements for both active pharmaceutical ingredients and finished medicinal products prior to clinical trials and marketing authorization applications.
She has previously held senior positions in research and development, formulation development, and regulatory authorities, working extensively with pharmaceutical quality and regulatory approval processes.
Chief Medical Officer
RegSmart Life Science
Marie Gårdmark (M.Sc. Pharm., PhD) has served as Regulatory Advisor to Auxesis since August 2024, focusing on preclinical and clinical development.
She has extensive experience from senior positions within both regulatory authorities and pharmaceutical research and development, with particular expertise in global regulatory strategies, due diligence, and scientific advice procedures within Europe and the United States.
Marie has broad experience across preclinical and clinical research, primarily within early-stage drug development and strategic development planning.
M.Sc. Chemical Engineering, Project Manager
Zelmic
Susanna Liljedahl has been a member of the ASA.P pharmaceutical development team since September 2024, with responsibility for formulation development and manufacturing of the Investigational Medicinal Product (IMP).
She is Project Manager at Zelmic and has more than ten years of experience as a researcher and project manager, including positions at AstraZeneca, specializing in pharmaceutical formulation and process development.
Susanna has served on executive management teams and led product and process development across several companies, with strong expertise in scalable development and quality-driven manufacturing.
Zelmic develops topical and transdermal pharmaceutical formulations and supports Auxesis in formulation development. They are an experienced, privately owned CRO and CDMO.
To Zelmic
AFRY supports Auxesis in planning and designing a sustainable production model. AFRY assists with medical research, regulatory processes and the development of future production capacity.
To AFRY
Auxesis collaborates with EIP on patents for ASA.P® and forthcoming patent applications. EIP has broad international expertise in drafting strong patent applications worldwide.
To EIP
Clinical Trial Consultants (CTC) is a specialized consultancy in clinical development, supporting pharmaceutical and medtech companies throughout the clinical process. With deep medical and regulatory expertise, CTC contributes to efficient study design, execution, and quality assurance across early and late clinical phases.
To CTC
Auxesis uses Edlund & Partners as its audit firm. Edlund & Partners has the competence, experience, and authorization to support companies in connection with stock exchange listings.
To Edlund & Partners
RegSmart Life Science AB supports Auxesis with regulatory matters related to the commercialization of ASA.P®. They help navigate a complex and evolving regulatory landscape.
To RegSmart Life Science
IQVIA and Svensk Läkemedelsstatistik provide accurate and comprehensive analyses of the pharmaceutical industry in Sweden and globally. Through thorough analysis and tailored consulting services, Auxesis gains valuable insights for decision-making.
To IQVIA and Svensk Läkemedelsstatistik
Ramberg Advokater in Stockholm is a full-service law firm with specialist expertise across multiple practice areas. Ramberg provides legal support to Auxesis, including commercial law, trademark matters, and a wide range of regulatory legal issues worldwide.
To RAMBERG Advokater